DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Kerendia is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.
This drug has fifty-four patent family members in forty-two countries.
The generic ingredient in KERENDIA is finerenone. One supplier is listed for this compound. Additional details are available on the finerenone profile page.
Kerendia will be eligible for patent challenges on July 9, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 12, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for KERENDIA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KERENDIA
|Drug Class||Nonsteroidal Mineralocorticoid-Receptor Antagonist |
|Mechanism of Action||Mineralocorticoid Receptor Antagonists |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Bayer Hlthcare||KERENDIA||finerenone||TABLET;ORAL||215341-001||Jul 9, 2021||RX||Yes||No||⤷ Try it Free||⤷ Try it Free||Y||Y||⤷ Try it Free|
|Bayer Hlthcare||KERENDIA||finerenone||TABLET;ORAL||215341-002||Jul 9, 2021||RX||Yes||Yes||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|Bayer Hlthcare||KERENDIA||finerenone||TABLET;ORAL||215341-001||Jul 9, 2021||RX||Yes||No||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|